Abstract:Background: Despite improved outcomes with the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR-activating mutations, unfortunately most patients eventually develop drug resistance. We and others recently reported that AXL activation confers acquired and intrinsic EGFR TKI resistance and represents a bypass resistance mechanism analogous to MET amplification in a subset of patients. This study aims to better assess the mechanisms whereby specific AXL inhibitors overcome such EGFR TKI resistance in NSCLC. Methods: AXL inhibitors including MGCD265 (glesatinib), MGCD516 (sitravatinib) and R428 (BGB-324) alone or in combination with erlotinib were used to test the inhibitory effect on EGFR TKI resistant NSCLC cells. Subsequently, the effects of single or combinational treatment on cell cycle and apoptosis were assessed. Then, RNA sequencing study was conducted to evaluate the dynamic gene expression profile changes and consequently based on key cellular pathway alterations studies of migration and EMT were pursued. Results: Administration of AXL inhibitors in combination with erlotinib significantly inhibited the growth of erlotinib-resistant NSCLC cells through potently inducing G2-M cell cycle arrest and enhancing apoptosis, relative to single agent treatment. RNA-sequencing analysis identified that several groups of genes enriched in cell survival inhibition or apoptosis promotion were upregulated, whereas genes enriched in DNA replication and repair, cell cycle and cell division were downregulated in cells treated with the combination of erlotinib and AXL inhibitor. Lastly, in line with pathway alterations indicating impaired migration, experiments showed reduced migration and EMT upon combination therapy. Conclusions: Our results indicate that effective blockade of the AXL pathway may represent a novel strategy to overcome EGFR TKI resistance for the treatment of biomarker-selected subsets of NSCLC patients.

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Supplementary Figure 4 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 5 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

The Role of Axl in Drug Resistance and Epithelial-to-mesenchymal Transition of Non-Small Cell Lung Carcinoma.

The Mir‑625‑3p/axl Axis Induces Non‑t790m Acquired Resistance to EGFR‑TKI Via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer.

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

MicroRNAs Reduce Tumor Growth and Contribute to Enhance Cytotoxicity Induced by Gefitinib in Non-Small Cell Lung Cancer

Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer

Microarray Expression Profile of Long Non-Coding Rnas in Egfr-Tkis Resistance of Human Non-Small Cell Lung Cancer

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

Microrna Expression Profiles Associated with Acquired Gefitinib-Resistance in Human Lung Adenocarcinoma Cells

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

Effect of AXL on the Epithelial-to-mesenchymal Transition in Non-Small Cell Lung Cancer

Axl Inhibitors As Novel Cancer Therapeutic Agents.

Epigenetic Silencing of Mir-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3